EAN

“Less is more” in medication-overuse headache

6668 2484 Peter Stevenson, PhD

Monitoring, recognition and effective patient education are cornerstones in the diagnosis and prevention of medication-overuse headache (MOH), delegates heard at the 5th Annual Congress of the European Academy of Neurology…

read more

Treating nature with NURTURE: Interim results of nusinersen for SMA

3473 2300 Mea Holm, PhD

Promising results for a disease-modifying treatment for spinal muscular atrophy (SMA) were presented at the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, last week.…

read more

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

3067 2300 Michael Furrer, PhD

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

read more

Serum NfL levels shine a light on neuroaxonal damage and disease

4089 2300 Michael Furrer, PhD

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

read more

Cellular power failures linked to Parkinsonism

3150 2100 Mea Holm, PhD

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

read more

8-year follow-up data of alemtuzumab presented

1920 1280 Michael Furrer, PhD

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

read more

The EAN President’s take on medical education

1024 625 Mea Holm, PhD

At the recent EAN 2018 congress, we met with Professor Franz Fazekas to discuss important advances and ongoing initiatives in medical education and continuous learning for neurologists. Prof. Fazekas is…

read more

Headaches and new ways to crush them

1800 1195 Mea Holm, PhD

At the ‘conference highlights’ session of the 2018 EAN meeting, Professor Isabel Pavão Martins presented a summary of the most groundbreaking research in the field of migraine. This highly burdensome…

read more

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

8001 4501 Mea Holm, PhD

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…

read more

Revolutionary therapies could make spinal muscular atrophy a distant memory

1200 675 Peter Stevenson, PhD

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular atrophy (SMA) – a severe…

read more
Brainwork is supported by unrestricted grants from: